Literature DB >> 28183993

Multiparametric Imaging of Tumor Hypoxia and Perfusion with 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer.

Milan Grkovski1, Heiko Schöder2, Nancy Y Lee3, Sean D Carlin2, Bradley J Beattie4, Nadeem Riaz3, Jonathan E Leeman3, Joseph A O'Donoghue4, John L Humm4.   

Abstract

Tumor hypoxia and perfusion are independent prognostic indicators of patient outcome. We developed the methodology for and investigated the utility of multiparametric imaging of tumor hypoxia and perfusion with 18F-fluoromisonidazole (18F-FMISO) dynamic PET (dPET) in head and neck cancer.
Methods: One hundred twenty head and neck cancer patients underwent 0- to 30-min 18F-FMISO dPET in a customized immobilization mask, followed by 10-min static acquisitions starting at 93 ± 6 and 160 ± 13 min after injection. A total of 248 lesions (≥2 cm3) were analyzed. Voxelwise pharmacokinetic modeling was conducted using an irreversible 1-plasma 2-tissue-compartment model to calculate surrogate biomarkers of tumor hypoxia (k3), perfusion (K1), and 18F-FMISO distribution volume. The analysis was repeated with truncated dPET datasets.
Results: Substantial inter- and intratumor heterogeneity was observed for all investigated metrics. Equilibration between the blood and unbound 18F-FMISO was rapid in all tumors. 18F-FMISO distribution volume deviated from the expected value of unity, causing discrepancy between k3 maps and total 18F-FMISO uptake and reducing the dynamic range of total 18F-FMISO uptake for quantifying the degree of hypoxia. Both positive and negative trends between hypoxia and perfusion were observed in individual lesions. All investigated metrics were reproducible when calculated from a truncated 20-min dataset.
Conclusion: 18F-FMISO dPET provides the data necessary to generate parametric maps of tumor hypoxia, perfusion, and radiotracer distribution volume. These data clarify the ambiguity in interpreting 18F-FMISO uptake and improve the characterization of lesions. We show total acquisition times can be reduced to 20 min, facilitating the translation of 18F-FMISO dPET into the clinic.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  18F-fluoromisonidazole; FMISO; dynamic PET; head and neck cancer; hypoxia; perfusion

Mesh:

Substances:

Year:  2017        PMID: 28183993      PMCID: PMC5493008          DOI: 10.2967/jnumed.116.188649

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  34 in total

1.  Multiparametric imaging of tumor response to therapy.

Authors:  Anwar R Padhani; Kenneth A Miles
Journal:  Radiology       Date:  2010-08       Impact factor: 11.105

2.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole.

Authors:  W J Koh; J S Rasey; M L Evans; J R Grierson; T K Lewellen; M M Graham; K A Krohn; T W Griffin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

3.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations.

Authors:  C S Patlak; R G Blasberg
Journal:  J Cereb Blood Flow Metab       Date:  1985-12       Impact factor: 6.200

Review 4.  Quantitative multimodality imaging in cancer research and therapy.

Authors:  Thomas E Yankeelov; Richard G Abramson; C Chad Quarles
Journal:  Nat Rev Clin Oncol       Date:  2014-08-12       Impact factor: 66.675

Review 5.  F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy.

Authors:  Joseph G Rajendran; Kenneth A Krohn
Journal:  Semin Nucl Med       Date:  2015-03       Impact factor: 4.446

6.  Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.

Authors:  David A Mankoff; Lisa K Dunnwald; Julie R Gralow; Georgiana K Ellis; Aaron Charlop; Thomas J Lawton; Erin K Schubert; Jeffrey Tseng; Robert B Livingston
Journal:  J Nucl Med       Date:  2002-04       Impact factor: 10.057

7.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.

Authors:  Susanne-Martina Eschmann; Frank Paulsen; Matthias Reimold; Helmut Dittmann; Stefan Welz; Gerald Reischl; Hans-Juergen Machulla; Roland Bares
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

8.  High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.

Authors:  Shozo Okamoto; Tohru Shiga; Koichi Yasuda; Yoichi M Ito; Keiichi Magota; Katsuhiko Kasai; Yuji Kuge; Hiroki Shirato; Nagara Tamaki
Journal:  J Nucl Med       Date:  2013-01-15       Impact factor: 10.057

9.  Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas.

Authors:  Anna S E Ljungkvist; Johan Bussink; Paulus F J W Rijken; Johannes H A M Kaanders; Albert J van der Kogel; Juliana Denekamp
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-09-01       Impact factor: 7.038

10.  Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer.

Authors:  Daniela Thorwarth; Susanne-Martina Eschmann; Jutta Scheiderbauer; Frank Paulsen; Markus Alber
Journal:  BMC Cancer       Date:  2005-12-01       Impact factor: 4.430

View more
  13 in total

1.  18F-Fluoromisonidazole Kinetic Modeling for Characterization of Tumor Perfusion and Hypoxia in Response to Antiangiogenic Therapy.

Authors:  Milan Grkovski; Sally-Ann Emmas; Sean D Carlin
Journal:  J Nucl Med       Date:  2017-03-30       Impact factor: 10.057

2.  Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic 18F-FMISO PET for Head and Neck Cancer Radiotherapy.

Authors:  Daniela Thorwarth; Stefan Welz; David Mönnich; Christina Pfannenberg; Konstantin Nikolaou; Matthias Reimold; Christian La Fougère; Gerald Reischl; Paul-Stefan Mauz; Frank Paulsen; Markus Alber; Claus Belka; Daniel Zips
Journal:  J Nucl Med       Date:  2019-05-10       Impact factor: 10.057

3.  The optimal 18F-fluoromisonidazole PET threshold to define tumor hypoxia in preclinical squamous cell carcinomas using pO2 electron paramagnetic resonance imaging as reference truth.

Authors:  Inna Gertsenshteyn; Boris Epel; Amandeep Ahluwalia; Heejong Kim; Xiaobing Fan; Eugene Barth; Marta Zamora; Erica Markiewicz; Hsiu-Ming Tsai; Subramanian Sundramoorthy; Lara Leoni; John Lukens; Mohammed Bhuiyan; Richard Freifelder; Anna Kucharski; Mihai Giurcanu; Brian B Roman; Gregory Karczmar; Chien-Min Kao; Howard Halpern; Chin-Tu Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07-06       Impact factor: 10.057

4.  Histometabolic Tumor Imaging of Hypoxia in Oral Cancer: Clinicopathological Correlation for Prediction of an Aggressive Phenotype.

Authors:  Grégoire B Morand; Martina A Broglie; Paul Schumann; Martin W Huellner; Niels J Rupp
Journal:  Front Oncol       Date:  2020-08-27       Impact factor: 6.244

Review 5.  The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.

Authors:  Robert H Press; Hui-Kuo G Shu; Hyunsuk Shim; James M Mountz; Brenda F Kurland; Richard L Wahl; Ella F Jones; Nola M Hylton; Elizabeth R Gerstner; Robert J Nordstrom; Lori Henderson; Karen A Kurdziel; Bhadrasain Vikram; Michael A Jacobs; Matthias Holdhoff; Edward Taylor; David A Jaffray; Lawrence H Schwartz; David A Mankoff; Paul E Kinahan; Hannah M Linden; Philippe Lambin; Thomas J Dilling; Daniel L Rubin; Lubomir Hadjiiski; John M Buatti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-06-30       Impact factor: 7.038

6.  Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer.

Authors:  Milan Grkovski; Nancy Y Lee; Heiko Schöder; Sean D Carlin; Bradley J Beattie; Nadeem Riaz; Jonathan E Leeman; Joseph A O'Donoghue; John L Humm
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-24       Impact factor: 9.236

7.  Quantification of Hypoxia in Human Glioblastoma using PET with 18F-FMISO.

Authors:  Redha-Alla Abdo; Frédéric Lamare; Philippe Fernandez; M'hamed Bentourkia
Journal:  Nucl Med Mol Imaging       Date:  2021-03-25

8.  Impact of tissue transport on PET hypoxia quantification in pancreatic tumours.

Authors:  Edward Taylor; Jennifer Gottwald; Ivan Yeung; Harald Keller; Michael Milosevic; Neesha C Dhani; Iram Siddiqui; David W Hedley; David A Jaffray
Journal:  EJNMMI Res       Date:  2017-12-22       Impact factor: 3.138

9.  Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.

Authors:  Nicole Wiedenmann; Hatice Bunea; Hans C Rischke; Andrei Bunea; Liette Majerus; Lars Bielak; Alexey Protopopov; Ute Ludwig; Martin Büchert; Christian Stoykow; Nils H Nicolay; Wolfgang A Weber; Michael Mix; Philipp T Meyer; Jürgen Hennig; Michael Bock; Anca L Grosu
Journal:  Radiat Oncol       Date:  2018-08-29       Impact factor: 3.481

10.  Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas.

Authors:  Kenta Suzuki; Nobuyuki Kawai; Tomoya Ogawa; Keisuke Miyake; Aya Shinomiya; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  EJNMMI Res       Date:  2021-07-21       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.